Genmab's van Berkel joins ADC Therapeutics
This article was originally published in Scrip
Executive Summary
ADC Therapeutics, a drug development company targeting cancer with antibody-drug conjugate therapies, has appointed former Genmab vice-president Dr Patrick van Berkel senior vice-president of R&D. Dr van Berkel served at Genmab for over nine years in different division, most recently as VP of chemistry, manufacturing and control, research & development since 2008.